Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
University of California, San Francisco
National Cancer Institute (NCI)
Fundación de investigación HM
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Seattle Children's Hospital
Nationwide Children's Hospital
Baylor College of Medicine
Nationwide Children's Hospital
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
University of Florida
National Cancer Institute (NCI)
Hoffmann-La Roche
University of Florida
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Cellectar Biosciences, Inc.
Children's National Research Institute
Washington University School of Medicine
City of Hope Medical Center
Endeavor Biomedicines, Inc.
Emory University
Eli Lilly and Company
Milton S. Hershey Medical Center
H. Lee Moffitt Cancer Center and Research Institute
C17 Council
Children's Oncology Group
Medical University of Vienna
Pediatric Brain Tumor Consortium
Milton S. Hershey Medical Center
Children's Oncology Group
Nationwide Children's Hospital
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Pediatric Brain Tumor Consortium
Dana-Farber Cancer Institute
Stanford University
Children's Oncology Group
The Hospital for Sick Children
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital